CRXT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 Sep 2022 @ 15:59):

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States...

Stats
Today's Volume	2.74M
Average Volume	0
Market Cap	0.00
EPS	$-1.390 ( Q2 \| 2022-08-19 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0170 (Sector) 42.63 (Industry) 61.14
ATR14	$0.0310 (65.26%)

CRXT -31.16%

MIRA -2.00%

SCLX 7.82%

SCLXW 5.24%

Insider Trading

Date	Person	Action	Amount	type
2022-06-07	Prygocki Mark A Sr	Buy	1 922	Common Stock
2022-06-07	Prygocki Mark A Sr	Buy	4 805	Stock Option (Right to Buy)
2022-06-07	Prygocki Mark A Sr	Buy	4 805	Stock Option (Right to Buy)
2022-06-07	Murphy Kimberly M	Buy	4 805	Stock Option (Right to Buy)
2022-06-07	Amory John Kenneth	Buy	1 922	Common Stock

INSIDER POWER
0.00
Last 40 transactions
Buy: 18 969 756 \| Sell: 5 390 412

Volume Correlation

Long: 0.70 (moderate)

Short: 0.84 (strong)

Signal:(22.284) Same movement expected

Clarus Therapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Clarus Therapeutics Correlation - Currency/Commodity

0.61
( weak )

0.37
( neutral )

0.00
( neutral )

0.33
( neutral )

-0.66
( moderate negative )

-0.49
( neutral )

Clarus Therapeutics Financials

Annual	2021
Revenue:	$13.96M
Gross Profit:	$11.24M (80.51 %)
EPS:	$-1.691

FY	2021
Revenue:	$13.96M
Gross Profit:	$11.24M (80.51 %)
EPS:	$-1.691

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.476

Financial Reports:

No articles found.

Clarus Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clarus Therapeutics

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill\'s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.